LabCorp Subsidiary Sequenom, Inc. Announces Expiration of and Final Tender Results for Tender Offers for 5% Convertible Senior Notes Due 2017 and 5% Convertible Senior Exchange Notes Due 2018

BURLINGTON, N.C. & SAN DIEGO --(BUSINESS WIRE)--Oct. 18, 2016-- Sequenom, Inc. (“Sequenom”), a wholly-owned subsidiary of Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH), announced the final results, as of 5:00 p.m. , New York City time, on Monday, October 17, 2016 (the

Covance Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award Three Years Running

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 12, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that Covance Drug Development (“Covance”) has been awarded the 2016 Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award.

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 3, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Subsidiary Sequenom, Inc. Announces Early Tender Results for Tender Offers and Successful Completion of Consent Solicitations for 5% Convertible Senior Notes Due 2017 and 5% Convertible Senior Exchange Notes Due 2018

BURLINGTON, N.C. & SAN DIEGO --(BUSINESS WIRE)--Sep. 30, 2016-- Sequenom, Inc. (“Sequenom”), a wholly-owned subsidiary of Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH), announced the results, as of 5:00 p.m. , New York City time, on September 29, 2016 (the “Early Tender

LabCorp Names Veteran Biopharma Executive John Ratliff CEO of Covance Drug Development

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 20, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH), the world’s leading healthcare diagnostics company, today announced that veteran biopharmaceutical executive John Ratliff will succeed Deborah Keller as CEO of Covance Drug

LabCorp Subsidiary Sequenom Inc. Announces Tender Offers and Consent Solicitations for 5% Convertible Senior Notes Due 2017 and 5% Convertible Senior Exchange Notes Due 2018

BURLINGTON, N.C. & SAN DIEGO --(BUSINESS WIRE)--Sep. 16, 2016-- Sequenom, Inc. , a wholly-owned subsidiary of Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH), announced the commencement of cash tender offers (the “Tender Offers”) for any and all of the outstanding 5%

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 12, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that for the period of September 12, 2016 to March 10, 2017 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

Laboratory Corporation of America® Holdings Successfully Completes Acquisition of Sequenom, Inc.

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 7, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the successful completion of the offering period for the cash tender offer by its direct wholly owned subsidiary, Savoy Acquisition Corp.

LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 6, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference . LabCorp’s presentation is planned for Monday, September 12, 2016 at 10:30 AM (ET) .

LabCorp’s Acquisition of Sequenom Clears Antitrust Review

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 23, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Sequenom, Inc.